ATE331806T1 - Gegen humanen vegf-rezeptor flt-1 gerichteter, monoklonaler antikörper. - Google Patents

Gegen humanen vegf-rezeptor flt-1 gerichteter, monoklonaler antikörper.

Info

Publication number
ATE331806T1
ATE331806T1 AT97913427T AT97913427T ATE331806T1 AT E331806 T1 ATE331806 T1 AT E331806T1 AT 97913427 T AT97913427 T AT 97913427T AT 97913427 T AT97913427 T AT 97913427T AT E331806 T1 ATE331806 T1 AT E331806T1
Authority
AT
Austria
Prior art keywords
human vegf
vegf receptor
monoclonal antibody
receptor flt
directed against
Prior art date
Application number
AT97913427T
Other languages
English (en)
Inventor
Kenya Shitara
Mikito Ito
Nobuo Hanai
Masabumi Shibuya
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Application granted granted Critical
Publication of ATE331806T1 publication Critical patent/ATE331806T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT97913427T 1996-11-21 1997-11-21 Gegen humanen vegf-rezeptor flt-1 gerichteter, monoklonaler antikörper. ATE331806T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP31110996 1996-11-21

Publications (1)

Publication Number Publication Date
ATE331806T1 true ATE331806T1 (de) 2006-07-15

Family

ID=18013261

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97913427T ATE331806T1 (de) 1996-11-21 1997-11-21 Gegen humanen vegf-rezeptor flt-1 gerichteter, monoklonaler antikörper.

Country Status (8)

Country Link
US (1) US6617160B1 (de)
EP (1) EP0882799B1 (de)
JP (1) JP3746790B2 (de)
AT (1) ATE331806T1 (de)
AU (1) AU731927B2 (de)
DE (1) DE69736222T2 (de)
ES (1) ES2267136T3 (de)
WO (1) WO1998022616A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
ATE331806T1 (de) 1996-11-21 2006-07-15 Kyowa Hakko Kogyo Kk Gegen humanen vegf-rezeptor flt-1 gerichteter, monoklonaler antikörper.
US6986890B1 (en) 1996-11-21 2006-01-17 Kyowa Hakko Kogyo Co., Ltd. Anti-human VEGF receptor Flt-1 monoclonal antibody
CA2313607A1 (en) * 1997-12-09 1999-06-17 Children's Medical Center Corporation Antagonists of neuropilin receptor function and use thereof
US6852533B1 (en) * 1998-01-23 2005-02-08 Cornell Research Foundation, Inc. Purified populations of stem cells
EP1086956B1 (de) * 1998-05-20 2009-04-15 Kyowa Hakko Kogyo Co., Ltd. Gen rekombinante antikörper
CA2328893A1 (en) * 1998-05-20 1999-11-25 Kyowa Hakko Kogyo Co., Ltd. Vegf activity inhibitors
JP3679406B2 (ja) * 1998-05-20 2005-08-03 協和醗酵工業株式会社 遺伝子組換え抗体
EP1160572A4 (de) * 1999-03-04 2002-03-20 Kyowa Hakko Kogyo Kk Mittel zur diagnose und therapie von leukämie
ATE410685T1 (de) * 1999-06-17 2008-10-15 Kyowa Hakko Kogyo Kk Diagnostikum und heilmittel für krankheiten unter teilnahme von makrozyten/makrophagen
EP1252177A1 (de) * 2000-02-04 2002-10-30 Supratek Pharma, Inc. Ligand für den vasculären endothelialen rezeptor des wachstumsfaktors
AU2001288058A1 (en) * 2000-10-11 2002-04-22 Orient Cancer Therapy Co., Ltd. Means of examining ability of angiogenesis
US20020137098A1 (en) * 2000-10-20 2002-09-26 Board Of Regents, The University Of Texas System Methods for detecting retinopathy of prematurity
JP2005508298A (ja) * 2001-06-20 2005-03-31 イムクローン システムズ インコーポレイティド アテローム性動脈硬化症及び他の炎症性疾患を処置する方法
US20050026220A1 (en) * 2001-08-10 2005-02-03 Shahin Rafii Isolation and mobilization of stem cells expressing vegfr-1
PT1916001E (pt) * 2002-03-04 2011-07-18 Imclone Llc Anticorpos humanos específicos para kdr e suas utilizações
US20050239088A1 (en) * 2003-05-16 2005-10-27 Shepard H M Intron fusion proteins, and methods of identifying and using same
US20070036795A1 (en) 2003-06-09 2007-02-15 Samuel Waksal Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular agonist
GB0323609D0 (en) * 2003-10-09 2003-11-12 Univ Belfast A peptide,and use of the peptide to assay for sflt-1 protein
EP1745073A2 (de) * 2004-05-14 2007-01-24 Receptor Biologix, Inc. Isoformen eines zelloberflächenrezeptors und verfahren zu deren identifizierung und anwendung
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
EP1812064A4 (de) 2004-11-19 2009-07-08 Cornell Res Foundation Inc Verwendung vaskulärer endothelwachstumsfaktor-rezeptor-1+-zellen bei der behandlung und überwachung von krebs und beim screening bei chemotherapie
JP5202956B2 (ja) * 2004-11-19 2013-06-05 コーネル リサーチ ファンデーション インコーポレーティッド 癌の治療およびモニタリングならびに化学療法薬に関するスクリーニングにおける血管内皮増殖因子受容体１＋細胞の使用法
EP1827602B1 (de) * 2004-11-26 2011-03-09 Novagali Pharma S.A. Modulierung der retinalen pigmentierten epithel-permeation durch hemmung von vegfr-1
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
KR100883430B1 (ko) 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
US9758571B2 (en) * 2012-07-20 2017-09-12 University—Industry Cooperation Group Of Kyung Hee University Antibody for epitope tagging, hybridoma cell line and uses thereof
CN111808191A (zh) * 2020-05-11 2020-10-23 廊坊天光生物技术有限公司 一种用于检测血清中vegf含量的抗体对及其用途
EP4547252A1 (de) 2022-06-30 2025-05-07 ICM (Institut du Cerveau et de la Moelle Épinière) Inhibitoren des vaskulären endothelialen wachstumsfaktorrezeptor-1 (vegfr-1) zur förderung der myelinisierung und neuroprotektion

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5830470A (en) 1992-09-07 1998-11-03 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
US5840301A (en) 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US5942385A (en) * 1996-03-21 1999-08-24 Sugen, Inc. Method for molecular diagnosis of tumor angiogenesis and metastasis
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
ATE331806T1 (de) 1996-11-21 2006-07-15 Kyowa Hakko Kogyo Kk Gegen humanen vegf-rezeptor flt-1 gerichteter, monoklonaler antikörper.

Also Published As

Publication number Publication date
EP0882799B1 (de) 2006-06-28
JP3746790B2 (ja) 2006-02-15
DE69736222D1 (de) 2006-08-10
AU731927B2 (en) 2001-04-05
US6617160B1 (en) 2003-09-09
ES2267136T3 (es) 2007-03-01
EP0882799A1 (de) 1998-12-09
WO1998022616A1 (fr) 1998-05-28
DE69736222T2 (de) 2007-05-24
AU5066698A (en) 1998-06-10
EP0882799A4 (de) 2002-05-29

Similar Documents

Publication Publication Date Title
DE69736222D1 (de) Gegen humanen vegf-rezeptor flt-1 gerichteter, monoklonaler antikörper.
ATE446973T1 (de) Anti-ccr2 antikörper sowie deren verwendung
EP1565489A4 (de) Neues raag10-zelloberflächenziel und dieses ziel erkennende antikörperfamilie
DE60226499D1 (de) Verwendung von antikörpern gegen das muc18-antigen
DK1616575T3 (da) Fremgangsmåde til behandling af inflammation
DE69633973D1 (de) Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor
ATE177475T1 (de) Monoklonale antikörper gegen c-kit
DE69929235D1 (de) Spiro-indole als y5-rezeptor antagonisten
ATE490275T1 (de) Antikörper gegen interleukin-22 und verwendungen dafür
DZ1700A1 (fr) Morpholine et thiomorpholine comme antagonistes des récepteurs de tachydinine.
DE69531290D1 (de) Antigen-besierende heteropolymere zur behandlung von autoimmunkrankheiten mittels diesen
DE69733179D1 (de) Modifizierte chimäre superantigene und deren verwendung
ES2293973T3 (es) Anticuerpos anti-ccr2 humanizados y metodos de uso de los mismos.
ATE309349T1 (de) Chemokinrezeptor 88c sowie dessen antikörper
DE69735294D1 (de) Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen
NO992916D0 (no) Fosfodiesterase 8A
EP0584715A3 (de) Gewinnung und Kultivierung transformierter Zellen und Herstellung gegen sie gerichteter Antikörper.
TR200102877T2 (tr) İmmünoglobulinin kendi yüksek afinite reseptörüne bağlanmasını inhibe eden antikorlara karşı anti-idiotipik antikorlar.
EE05497B1 (et) Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
ATE171473T1 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
ATE428732T1 (de) Gen rekombinante antikörper
ATE388168T1 (de) Antikörper gegen den il-8 rezeptor und deren therapeutische verwendungen
GR852149B (de)
CA2243302A1 (en) Anti-human vegf receptor f1t-1 monoclonal antibody
WO2002064023A3 (en) Fra-1 expression in brain cancer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties